A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management
<p>Hypomethylating drugs are useful and approved in the management of myelodysplastic syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). However, phase 2 and 3 studies that assessed these agents in MDS, have included only a small number of CMML, and there are only few specific...
Saved in:
Main Authors: | Elena Elli, Caterina Cecchetti, Angelo Belotti, Lorenza Borin, Enrico Maria Pogliani |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2012-01-01
|
Series: | Mediterranean Journal of Hematology and Infectious Diseases |
Subjects: | |
Online Access: | http://www.mjhid.org/article/view/10013 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
AZACITIDINE IN CHRONIC MYELOMONOCYTIC LEUKEMIA: AN EFFECTIVE AND MANAGEABLE APPROACH.
by: Pasquale Niscola
Published: (2014-02-01) -
Unusual transformation from refractory anemia to chronic myelomonocytic leukemia: a case report.
by: Pasquale Niscola
Published: (2014-08-01) -
Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with DDX41 mutations
by: Xin Wang, et al.
Published: (2024-12-01) -
INFECTIONS IN MYELODYSPLASTIC SYNDROME IN RELATION TO STAGE AND THERAPY
by: Giuseppe Leone, et al.
Published: (2018-07-01) -
Survival Outcomes of U.S. Patients with CMML: A Two-Decade Analysis from the SEER Database
by: Ayrton Bangolo, et al.
Published: (2024-10-01)